Chorionic gonadotropin 1500 units vials №5 + solvent

Packaging

5 pieces

Mechanism of action

Chorionic gonadotropin - gonadotropic hormone. It is produced by human placenta and excreted into the urine, from where it can be extracted and cleaned. Stimulates the production of Progesterone by the corpus luteum and supports the development of the placenta. It has a gonadotropic effect, mainly luteinizing.

In women, the drug causes ovulation and stimulates the synthesis of estrogen and progesterone. In men, it stimulates spermatogenesis and the production of sex steroids.

Pharmacokinetics

After the / m injection is well absorbed. T1 / 2 is 8 hours.

It is believed that before excretion with urine, chorionic gonadotropin is modified in the body, since its T1 / 2, measured by the immunological method, significantly exceeds this indicator, determined by biological activity.

Indications and usage

For women: induction of ovulation after stimulation of follicle growth; maintaining the function of the corpus luteum of the ovary in patients with luteal phase insufficiency.

For boys and men: cryptorchidism (ectopia, testicular retention in the abdominal cavity or in the inguinal canal); delayed puberty; hypogonadotropic hypogonadism (in combination with human menopausal gonadotropin preparations); during the differential diagnostic test for anorchism and cryptorchidism in boys; when conducting a functional Leydig test to assess the function of the testicles in hypogonadotropic hypogonadism before beginning a long-term stimulatory treatment

Contraindications

• Tumors of various localization, dependent on sex hormones;
• organically-induced cryptorchidism (inguinal hernia, consequences of surgical interventions in the inguinal region, abnormal position of the testicles) in boys and men;
• hypersensitivity to human chorionic gonadotropin.

Solutions are prepared immediately before use in an isotonic solution of sodium chloride. It is necessary to take into account the probability of false-positive results of immunological analysis for the content of endogenous chronic hepatitis and the possibility of increasing the concentration of 17-hydroxycorticosteroids and 17-ketosteroids in the urine.

Active ingredient

1 bottle contains:

Active substance: chorionic gonadotropin 1500 UNITS

Dosage and administration

Chorionic gonadotropin administered intramuscularly.The dose is individualized depending on the nature, severity of the disease and the age of the patient and ranges from 500 to 3000 units per day.

For men, the drug is administered 2-3 times a week in courses of 4 weeks at intervals of 4-6 weeks. Conduct 3-6 courses for 6-12 months. Prolonged continuous use of the drug is not recommended due to the risk of antibody formation and suppression of the pituitary gonadotropic function.

With anovulatory cycles with a high level of estrogen in women, which indicates the normal maturation of the follicles, the drug is administered from the 10th to the 12th day of the cycle, 3000 IU 2-3 times with an interval of 2-3 days or 1500 IU 6-7 times day.

In interstitial-pituitary insufficiency, treatment with chorionic gonadotropin is best performed after prior treatment in the first phase of the cycle with follicle-stimulating hormone. In case of pituitary nanizm with symptoms of sexual infantilism, the drug is administered in a dose of 500-1000 IU 1-2 times a week for 1-2 months with repeated courses.

Treatment of gonadotropin chorionic cryptorchidism in children is most effective at the age of 10 years. Dosage and duration of treatment are individual, depending on the location of the undescended testicle and the nature of cryptorchidism (single or double sided). The following treatment regimen is most common: for cryptorchidism in children under the age of 10 years, 500-1000 IU is administered, and at the age of 10–14 years, 1500 IU 2 times a week for 4-6 weeks with repeated courses.

For diagnostic purposes, the drug is administered to men for 1500-3000 IU per day for 5 days. With a positive result, daily urine excretion of 17-ketosteroids and testosterone increases.

Adverse reactions

On the part of the endocrine system in women:ovarian hyperstimulation syndrome may develop, accompanied by the development of ovarian cysts with the risk of rupture, ascites, hydrothorax, and the risk of thromboembolism.

On the part of the endocrine system in boys and men: temporary reversible enlargement of the mammary glands, prostate gland, water and electrolyte retention, and acne are possible; in boys, behavioral changes similar to those observed during the first phase of puberty, which take place after the end of treatment, are possible.

Drug interactions

Chorionic gonadotropin is used in combination with menopausal gonadotropin in the treatment of infertility.

Storage conditions

In a dark place, out of reach of children, at a temperature not exceeding 20 ° C.